Charles Li
Contact information
Research groups
Colleges
Charles Li
BA (Hons)
DPhil student
Charles joined the China Kadoorie Biobank research unit as a DPhil student in October 2023. Under the supervision of Professors Huaidong Du, Iona Millwood, and Derrick Bennett, his research examines potential therapeutic targets for glaucoma and other eye diseases using proteogenomic data from prospective biobank studies.
Charles earned a BA (Hons) in Molecular and Cell Biology from the University of California, Berkeley. There, he had the opportunity to contribute to an international research collaboration on optimizing infectious disease surveillance networks that was led by the UC Berkeley School of Public Health and the Chinese Center for Disease Control and Prevention (China CDC), where he was hosted for three summers as a visiting researcher in Chengdu, Sichuan. Afterwards, Charles joined the data science and analytics team of the American Academy of Ophthalmology to conduct observational research on key topics in ophthalmology and eye care using a multimillion-patient national ocular disease registry.
Recent publications
-
Prevalence and Risk Factors of Blindness Among Primary Angle Closure Glaucoma Patients in the United States: An IRIS® Registry Analysis.
Journal article
Shah SN. et al, (2023), Am J Ophthalmol
-
The impact of month and season on the incidence of giant cell arteritis: an Intelligent Research in Sight (IRIS) Registry analysis.
Journal article
Wladis EJ. et al, (2023), Graefes Arch Clin Exp Ophthalmol
-
Vitreoretinopathy-Associated Pediatric Retinal Detachment Treatment Outcomes: IRIS® Registry (Intelligent Research in Sight) Analysis.
Journal article
Belin PJ. et al, (2023), Ophthalmol Sci, 3
-
Timing of Delayed Retinal Pathology in Patients Presenting with Acute Posterior Vitreous Detachment in the IRIS® Registry (Intelligent Research in Sight).
Journal article
Vangipuram G. et al, (2023), Ophthalmol Retina, 7, 713 - 720
-
Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti-VEGF Therapy in the United States in the IRIS® Registry.
Journal article
Khurana RN. et al, (2023), Ophthalmology, 130, 672 - 683